Pathogenic Variants in Complement Genes and Risk of Atypical Hemolytic Uremic Syndrome Relapse after Eculizumab Discontinuation

BACKGROUND AND OBJECTIVES: The complement inhibitor eculizumab has dramatically improved the outcome of atypical hemolytic uremic syndrome. However, the optimal duration of eculizumab treatment in atypical hemolytic uremic syndrome remains debated. We report on the French atypical hemolytic uremic s...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Clin J Am Soc Nephrol
Autors principals: Fakhouri, Fadi, Fila, Marc, Provôt, François, Delmas, Yahsou, Barbet, Christelle, Châtelet, Valérie, Rafat, Cédric, Cailliez, Mathilde, Hogan, Julien, Servais, Aude, Karras, Alexandre, Makdassi, Raifah, Louillet, Feriell, Coindre, Jean-Philippe, Rondeau, Eric, Loirat, Chantal, Frémeaux-Bacchi, Véronique
Format: Artigo
Idioma:Inglês
Publicat: American Society of Nephrology 2017
Matèries:
Original Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5220663/
https://ncbi.nlm.nih.gov/pubmed/27799617
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2215/CJN.06440616
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars